Skip to main content
. 2020 Nov 18;10:20058. doi: 10.1038/s41598-020-77023-z

Figure 1.

Figure 1

Incremental risk (%) of conversion associated to significant additive interactions and the corresponding main effects of APOE ε4 and NPS. The incremental risk is calculated considering patients APOE ε4 noncarriers and without NPS symptoms as the reference condition.